Positioned to disrupt the medicinal industry with its wide range of products and significant stakes in other biotech companies like Compass. ATAI possess ample funds to quickly become a leader in a market that has not yet fully emerged. High Volatility I wouldn't be surprised to see the stock reach $20 next year, analysts predict $11.
Weekly RSI looks great and primed to run showing strength above 50 with key MA overhead
The daily is getting a little hot pullbacks will offer great opportunities.
Weekly RSI looks great and primed to run showing strength above 50 with key MA overhead
The daily is getting a little hot pullbacks will offer great opportunities.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.